Ольга Викторовна Иванова
Research Subjects
Ольга Викторовна Иванова has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Dmitry Aleksandrovich Bakulin
Volgograd State Medical University
8 shared publications - Yu. A. Kolosov
ROSUNIMED
8 shared publications - Denis Vladimirovich Kurkin
Russian University of Medicine. 2. Volgograd State Medical University
7 shared publications - Evgeniy I. Morkovin
Volgograd State Medical University
7 shared publications - Ivan S. Krysanov
Moscow State University of Food Production
6 shared publications - Andrei V. Strygin
Volgograd State Medical University
5 shared publications
Latest Publications
- Open Access
- 29 November 2025
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 13 (6) , 432-486
Review of medicines approved by the Food and Drug Administration from 2012 to 2024
The aim . To describe the key characteristics of medical products approved by the Food and Drug Administration (FDA) and released by pharmaceutical companies from 2012 to 2024. Materials and methods. The analysis is based on data from FDA publications related to the approval of medical products from 2012 to 2024. The products were systematized by year, pathway and reason for approval, nature of the active substance (synthetic, semi-synthetic, natural or biological) and target disease (indication for use) in accordance with the codes of the Anatomical Therapeutic Chemical (ATC) classification. Results . During the analyzed period, the FDA approved a significant number of medicines, while maintaining a stable proportion of small molecules with a significant upward trend in the number of approved biologicals (monoclonal antibodies, CAR-T, siRNA, gene therapy, etc.). The largest proportion was accounted for by antitumor drugs and immunomodulators (group L according to ATC), demonstrating steady growth with projected growth in the future. Interest in drugs for the treatment of metabolic disorders and diseases of the nervous system remained steadily high, with the emergence of innovative therapeutic approaches. A gradual increase in the number of repositionings and extensions of indications was noted. The COVID-19 pandemic did not have a significant impact on the overall structure of approvals, and only two specific medicines for the treatment of COVID-19 were approved. There has been an increase in approvals for orphan diseases and the emergence of innovative therapeutic approaches: gene therapy, RNA interference, cell technologies, and bispecific antibodies. Conclusion. In the period from 2012 to 2024, the pharmaceutical industry has seen a fundamental shift towards biotechnological development methods, personalized medicine, and targeted therapy. During the period under review, the proportion of small molecule approvals remained fairly stable, but a steady (compared to previous periods) increase in the number of biotechnology product approvals (monoclonal antibodies, gene and RNA therapy) can be noted. The largest increase was noted in class L (antitumor drugs and immunomodulators), which reflects the focus of global pharmaceutical companies on the fundamental study and discovery of pharmacotherapy opportunities in the oncology and immunity. It is necessary to note the trend towards the development of drugs for the treatment of rare (orphan) diseases. In the field of therapy for metabolic disorders, during the specified period, drugs were approved that revolutionized understanding of an entire cluster of diseases and approaches to therapy, and a new standard of therapy was formed due to SGLT2 inhibitors and agonists of the incretin system receptors, including molecules with a multi-targeted effect. The COVID-19 pandemic led to a limited number of drug approvals for the treatment of this infection but thanks to it, the “door” to the development of new generation vaccines has been opened, which are largely fundamentally different from those currently existing. The discovery of new means to combat infectious agents of various nature (bacteria, protozoa, viruses, fungi, and parasites) is also one of the priority goals of pharmaceutical companies, as evidenced by a significant proportion of approvals of drugs with a similar effect. In terms of “reasons for registration,” the main share fell on original drugs; the contribution of new combinations and dosage forms was at its peak in the middle of the period and then decreased. Due to the expiration of patent protection for many drugs and the accumulation of data on their effects in the post-marketing period, a gradual increase in the number of repositionings and extensions of indications can be logically noted.
- 29 November 2025
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 13 (6) , 432-486
Open AccessReview of medicines approved by the Food and Drug Administration from 2012 to 2024
The aim . To describe the key characteristics of medical products approved by the Food and Drug Administration (FDA) and released by pharmaceutical companies from 2012 to 2024. Materials and methods. The analysis is based on data from FDA publications related to the approval of medical products from 2012 to 2024. The products were systematized by year, pathway and reason for approval, nature of the active substance (synthetic, semi-synthetic, natural or biological) and target disease (indication for use) in accordance with the codes of the Anatomical Therapeutic Chemical (ATC) classification. Results . During the analyzed period, the FDA approved a significant number of medicines, while maintaining a stable proportion of small molecules with a significant upward trend in the number of approved biologicals (monoclonal antibodies, CAR-T, siRNA, gene therapy, etc.). The largest proportion was accounted for by antitumor drugs and immunomodulators (group L according to ATC), demonstrating steady growth with projected growth in the future. Interest in drugs for the treatment of metabolic disorders and diseases of the nervous system remained steadily high, with the emergence of innovative therapeutic approaches. A gradual increase in the number of repositionings and extensions of indications was noted. The COVID-19 pandemic did not have a significant impact on the overall structure of approvals, and only two specific medicines for the treatment of COVID-19 were approved. There has been an increase in approvals for orphan diseases and the emergence of innovative therapeutic approaches: gene therapy, RNA interference, cell technologies, and bispecific antibodies. Conclusion. In the period from 2012 to 2024, the pharmaceutical industry has seen a fundamental shift towards biotechnological development methods, personalized medicine, and targeted therapy. During the period under review, the proportion of small molecule approvals remained fairly stable, but a steady (compared to previous periods) increase in the number of biotechnology product approvals (monoclonal antibodies, gene and RNA therapy) can be noted. The largest increase was noted in class L (antitumor drugs and immunomodulators), which reflects the focus of global pharmaceutical companies on the fundamental study and discovery of pharmacotherapy opportunities in the oncology and immunity. It is necessary to note the trend towards the development of drugs for the treatment of rare (orphan) diseases. In the field of therapy for metabolic disorders, during the specified period, drugs were approved that revolutionized understanding of an entire cluster of diseases and approaches to therapy, and a new standard of therapy was formed due to SGLT2 inhibitors and agonists of the incretin system receptors, including molecules with a multi-targeted effect. The COVID-19 pandemic led to a limited number of drug approvals for the treatment of this infection but thanks to it, the “door” to the development of new generation vaccines has been opened, which are largely fundamentally different from those currently existing. The discovery of new means to combat infectious agents of various nature (bacteria, protozoa, viruses, fungi, and parasites) is also one of the priority goals of pharmaceutical companies, as evidenced by a significant proportion of approvals of drugs with a similar effect. In terms of “reasons for registration,” the main share fell on original drugs; the contribution of new combinations and dosage forms was at its peak in the middle of the period and then decreased. Due to the expiration of patent protection for many drugs and the accumulation of data on their effects in the post-marketing period, a gradual increase in the number of repositionings and extensions of indications can be logically noted.
- Open Access
- 25 November 2024
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 12 (2) , 131-149
Analysis of Russian pharmaceutical specialists labor market for 2019–2022
The higher education system is becoming more and more competitive every year. It faces ambitious tasks of training highly qualified personnel and ensuring technological sovereignty. A labor market analysis is an integral component of the early career guidance work with students and their navigation in the profession, which is especially important at the beginning of their employment.The aim of the work was to conduct a comparative analysis of supply and demand indicators in the labor market of pharmaceutical specialists in nine Russian regions in 2019–2022.Materials and methods. The research methodology included the collection, quantitative and qualitative analyses of the data on the SuperJob.ru website. The posted offers (vacancies) and CVs were analyzed on the portal SuperJob.ru (a large online service of CVs and vacancies from direct employers, agencies, employment centers) for 2019–2022 in nine regions and federal districts of Russia: Moscow and the Moscow region, St. Petersburg and the Leningrad region, the Central Federal District (without the Moscow region), the Northwestern Federal District (without the Leningrad Region), the Volga Federal District, the Urals Federal District, the Siberian Federal District, the Far Eastern Federal District, the Southern and North Caucasus Federal Districts.Results. The analysis of the number of posted vacancies and CVs in the recruitment agency database for 2019–2022 shows a stable shortage of pharmacy professionals with both secondary (vacancies / CVs – 42112 / 41037) and higher professional education (vacancies / CVs – 36432 / 25149). The pointed out specialists are among the most required ones by employers, and pharmacy is one of the most popular areas for candidates. Cities with a high level of economy and population experience a greater deficit in specialists with pharmaceutical education. Salary levels of specialists with higher or secondary education are almost comparable on average from 50 to 75 thousand rubles, but employers generally prefer to hire specialists with higher education.Conclusion. On average in the regions, the demand for specialists with higher education is lower than the demand for specialists with secondary education and the salary expectations of pharmacists coincide with the employers’ offers, while the salary expectations of specialists with higher education are higher in the market. Specialists with secondary education are much more numerous, as they are trained by a much larger number of educational institutions. For pharmacy technicians, a pharmacy is often the only place of work in their specialty, while for pharmacists it is usually a starting point.
- 25 November 2024
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 12 (2) , 131-149
Open AccessAnalysis of Russian pharmaceutical specialists labor market for 2019–2022
The higher education system is becoming more and more competitive every year. It faces ambitious tasks of training highly qualified personnel and ensuring technological sovereignty. A labor market analysis is an integral component of the early career guidance work with students and their navigation in the profession, which is especially important at the beginning of their employment.The aim of the work was to conduct a comparative analysis of supply and demand indicators in the labor market of pharmaceutical specialists in nine Russian regions in 2019–2022.Materials and methods. The research methodology included the collection, quantitative and qualitative analyses of the data on the SuperJob.ru website. The posted offers (vacancies) and CVs were analyzed on the portal SuperJob.ru (a large online service of CVs and vacancies from direct employers, agencies, employment centers) for 2019–2022 in nine regions and federal districts of Russia: Moscow and the Moscow region, St. Petersburg and the Leningrad region, the Central Federal District (without the Moscow region), the Northwestern Federal District (without the Leningrad Region), the Volga Federal District, the Urals Federal District, the Siberian Federal District, the Far Eastern Federal District, the Southern and North Caucasus Federal Districts.Results. The analysis of the number of posted vacancies and CVs in the recruitment agency database for 2019–2022 shows a stable shortage of pharmacy professionals with both secondary (vacancies / CVs – 42112 / 41037) and higher professional education (vacancies / CVs – 36432 / 25149). The pointed out specialists are among the most required ones by employers, and pharmacy is one of the most popular areas for candidates. Cities with a high level of economy and population experience a greater deficit in specialists with pharmaceutical education. Salary levels of specialists with higher or secondary education are almost comparable on average from 50 to 75 thousand rubles, but employers generally prefer to hire specialists with higher education.Conclusion. On average in the regions, the demand for specialists with higher education is lower than the demand for specialists with secondary education and the salary expectations of pharmacists coincide with the employers’ offers, while the salary expectations of specialists with higher education are higher in the market. Specialists with secondary education are much more numerous, as they are trained by a much larger number of educational institutions. For pharmacy technicians, a pharmacy is often the only place of work in their specialty, while for pharmacists it is usually a starting point.
- 30 July 2024
- Published by Folium Publishing Company in Химико-фармацевтический журнал
- Vol. 58 (7) , 3-12
Талидомид: история исследования и перспективы медицинского применения (обзор)
Талидомид применялся в 1950-х гг. в качестве седативного средства. Из-за выраженной тератогенности он был удален с рынка в 1960-х гг., а 40 лет спустя возвращен в клинику как противоопухолевое средство. Сейчас талидомид и его производные (IMiDs и CELMoDs) активно применяются для лечения некоторых гематологических опухолей. Спектр его свойств включает иммуномодулирующее, противовоспалительное и антиангиогенное действие, отмечается нейропротекторный и анальгетический потенциал. Талидомид взаимодействует с компонентом убиквитин-лигазного комплекса (белок цереблон), меняя его специфичность, что приводит к протеасомной деградации ряда неосубстратов, в том числе факторов транскрипции, важных для эмбрионального развития (SALL4, p63, PLZF), ключевых для гематологических опухолей (Ikaros, Aiolos, CK1α и др.) и регулирующих экспрессию мРНК ФНО-α. Раскрытие мишени способствовало быстрому развитию технологии PROTAC в рамках поиска способа внутриклеточной деградации целевых белков. В работе описаны некоторые исследования, посвященные современному применению талидомида и его аналогов.
- 30 July 2024
- Published by Folium Publishing Company in Химико-фармацевтический журнал
- Vol. 58 (7) , 3-12
Талидомид: история исследования и перспективы медицинского применения (обзор)
Талидомид применялся в 1950-х гг. в качестве седативного средства. Из-за выраженной тератогенности он был удален с рынка в 1960-х гг., а 40 лет спустя возвращен в клинику как противоопухолевое средство. Сейчас талидомид и его производные (IMiDs и CELMoDs) активно применяются для лечения некоторых гематологических опухолей. Спектр его свойств включает иммуномодулирующее, противовоспалительное и антиангиогенное действие, отмечается нейропротекторный и анальгетический потенциал. Талидомид взаимодействует с компонентом убиквитин-лигазного комплекса (белок цереблон), меняя его специфичность, что приводит к протеасомной деградации ряда неосубстратов, в том числе факторов транскрипции, важных для эмбрионального развития (SALL4, p63, PLZF), ключевых для гематологических опухолей (Ikaros, Aiolos, CK1α и др.) и регулирующих экспрессию мРНК ФНО-α. Раскрытие мишени способствовало быстрому развитию технологии PROTAC в рамках поиска способа внутриклеточной деградации целевых белков. В работе описаны некоторые исследования, посвященные современному применению талидомида и его аналогов.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (5) , 22-30
Targeting NMDAR/AMPAR: a promising pharmacotherapeutic approach for depressive disorders
Depression is a leading cause of disability and reduced work capacity worldwide. The monoamine theory of the pathogenesis of depression has remained dominant for many decades, however, drugs developed on its basis have limited efficacy. Exploring alternative mechanisms underlying this pathology could illuminate new avenues for pharmacological intervention. Targeting glutamatergic pathways in the CNS, particularly through modulation of NMDA and AMPA receptors, demonstrates promising results. This review presents some existing drugs with glutamatergic activity and novel developments based on it to enhance the efficacy of pharmacotherapy for depressive disorders.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (5) , 22-30
Targeting NMDAR/AMPAR: a promising pharmacotherapeutic approach for depressive disorders
Depression is a leading cause of disability and reduced work capacity worldwide. The monoamine theory of the pathogenesis of depression has remained dominant for many decades, however, drugs developed on its basis have limited efficacy. Exploring alternative mechanisms underlying this pathology could illuminate new avenues for pharmacological intervention. Targeting glutamatergic pathways in the CNS, particularly through modulation of NMDA and AMPA receptors, demonstrates promising results. This review presents some existing drugs with glutamatergic activity and novel developments based on it to enhance the efficacy of pharmacotherapy for depressive disorders.
- Open Access
- 29 January 2024
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 11 (5) , 384-398-398
Methodological and regulatory aspects of pharmaceutical development of biological products
The aim of the work was to conduct an analysis of the current state and current trends in the approval of drugs, as well as some aspects of the methodology for their development based on biological molecules and registration.Materials and methods. The material for the analysis was taken from the abstract databases of PubMed, Google Scholar and e-library.ru. The search was carried out using publications for the period from 2008 to 2023, the keywords were as follows: “biologicals”, “new drug approval”, “drug authorization”, “drug development”, “biosimilar”, taking into account various spellings.Results. Over the past 15 years, scientists have been observing revolutionary trends and processes in the field of the drug development, especially biopharmaceuticals. Significant advances have been made in gene, immune and cell therapies, resulting in the approval of such drugs more than doubling over the past ten years. The development of biological drugs includes the identification and testing of molecular targets and requires a deep understanding of the structure and functioning of the polypeptides involved in the development of the effect. The features of these active pharmaceutical substances are a high molecular weight, a complex three-dimensional structure and a high immunogenic potential. Preclinical and clinical studies of biologics have unique challenges. Selecting appropriate animal species, understanding the immunogenicity, and assessing pharmacodynamics and toxicological properties require a multilevel, detailed approach. The article discusses the regulatory framework under which these drugs are registered, summarizing the guidelines provided by international organizations such as the International Council for Harmonization and various national agencies.Conclusion. The analysis highlights the current advances and prospects in the development of biologics, highlighting their key role in future transformations in the treatment of rare diseases and oncology, approaching the era of personalized medicine. Monitoring the development directions and technological approaches, as well as the commitment to global methodological and regulatory aspects can become a catalyst in the development of the Russian pharmacology.
- 29 January 2024
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 11 (5) , 384-398-398
Open AccessMethodological and regulatory aspects of pharmaceutical development of biological products
The aim of the work was to conduct an analysis of the current state and current trends in the approval of drugs, as well as some aspects of the methodology for their development based on biological molecules and registration.Materials and methods. The material for the analysis was taken from the abstract databases of PubMed, Google Scholar and e-library.ru. The search was carried out using publications for the period from 2008 to 2023, the keywords were as follows: “biologicals”, “new drug approval”, “drug authorization”, “drug development”, “biosimilar”, taking into account various spellings.Results. Over the past 15 years, scientists have been observing revolutionary trends and processes in the field of the drug development, especially biopharmaceuticals. Significant advances have been made in gene, immune and cell therapies, resulting in the approval of such drugs more than doubling over the past ten years. The development of biological drugs includes the identification and testing of molecular targets and requires a deep understanding of the structure and functioning of the polypeptides involved in the development of the effect. The features of these active pharmaceutical substances are a high molecular weight, a complex three-dimensional structure and a high immunogenic potential. Preclinical and clinical studies of biologics have unique challenges. Selecting appropriate animal species, understanding the immunogenicity, and assessing pharmacodynamics and toxicological properties require a multilevel, detailed approach. The article discusses the regulatory framework under which these drugs are registered, summarizing the guidelines provided by international organizations such as the International Council for Harmonization and various national agencies.Conclusion. The analysis highlights the current advances and prospects in the development of biologics, highlighting their key role in future transformations in the treatment of rare diseases and oncology, approaching the era of personalized medicine. Monitoring the development directions and technological approaches, as well as the commitment to global methodological and regulatory aspects can become a catalyst in the development of the Russian pharmacology.
- Open Access
- 24 January 2024
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 69 (6) , 86-101
Evolution of insulin therapy: past, present, future
2021 marks the 100th anniversary of the discovery of insulin, an event that forever changed the lives of people with diabetes mellitus. At present patients around the world experience the miracle of insulin therapy every day. A disease that used to kill children and teenagers in 2 years in 1920 has become a disease that can be controlled with a possibility to lead a long productive life. Over the past century, the great discovery of Banting, Best and Collip has forever changed the world and saved millions of lives. This review is devoted to the history of the development of insulin and its further improvement: from the moment of discovery to the present days. Various generations of insulin are considered: from animals to modern ultrashort and basal analogues. The article ends with a brief review of current trends in the development of new delivery methods and the development of new insulin molecules. Over the past century, insulin therapy has come a long way, which has significantly improved the quality of life of our patients. But research is actively continuing, including in the field of alternative methods of insulin delivery, which are more convenient for the patient, as well as in the development of «smart» molecules that will have a glucose-dependent effect.
- 24 January 2024
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 69 (6) , 86-101
Open AccessEvolution of insulin therapy: past, present, future
2021 marks the 100th anniversary of the discovery of insulin, an event that forever changed the lives of people with diabetes mellitus. At present patients around the world experience the miracle of insulin therapy every day. A disease that used to kill children and teenagers in 2 years in 1920 has become a disease that can be controlled with a possibility to lead a long productive life. Over the past century, the great discovery of Banting, Best and Collip has forever changed the world and saved millions of lives. This review is devoted to the history of the development of insulin and its further improvement: from the moment of discovery to the present days. Various generations of insulin are considered: from animals to modern ultrashort and basal analogues. The article ends with a brief review of current trends in the development of new delivery methods and the development of new insulin molecules. Over the past century, insulin therapy has come a long way, which has significantly improved the quality of life of our patients. But research is actively continuing, including in the field of alternative methods of insulin delivery, which are more convenient for the patient, as well as in the development of «smart» molecules that will have a glucose-dependent effect.
- Open Access
- 9 January 2024
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 11 (4) , 347-380-380
Physiology and pharmacology of glucagon-like peptide-1 receptor
Modern approaches to the treatment of type 2 diabetes mellitus (T2DM) are aimed not only at glycemic control, but also at reducing cardiovascular risks. The increasing prevalence of the disease and the need for effective treatment options highlight the importance of glucagon-like peptide-1 (GLP-1) receptor agonists in the pharmacotherapy structure.The aim of the work was to review the literature regarding the physiology of GLP-1 and the therapeutic potential and development trends of its agonists.Materials and methods. The search for the review materials was carried out using the abstract databases of PubMed, Google Scholar and e-Library. The search was carried out for publications from 2000 to 2023, using the following keywords: “GLP-1”; “GLP-1R agonists”; “GIP”; “exenatide”; “liraglutide”; “dulaglutide”; “semaglutide”; “lixisenatide”; “albiglutide”; “taspoglutide” taking into account various spellings.Results. The interaction of almost all food components with enteroendocrine cells of the intestine leads to the secretion of incretins (primarily GLP-1) into the blood, triggering a complex of physiological reactions aimed primarily at the rapid utilization of incoming glucose (regulation of insulin and glucagon secretion), as well as the central regulation of dietary behavior (slowing gastric emptying and the formation of a feeling of satiety). A wide distribution of the GLP-1 receptor in various tissues and organs, its connection with intracellular signaling cascades aimed at launching energy-consuming remodeling (recovery) processes in endothelial cells, heart, neurons, beta cells, etc., is the basis for a wide range of pleiotropic effects of GLP-1 unrelated to its hypoglycemic effect. The discovery of synthetic GLP-1 receptor agonists with a long period of action has made it possible not only to therapeutically influence various parts of carbohydrate metabolism disorders, but also to increase the functional reserves of the target diabetes organs, reducing the risk of developing complications of the disease. Incretin-like drugs are well tolerated, with nausea being the most common side effect. The factors limiting a wider use of the drugs include their high cost and the preferred form of a subcutaneous solution. The current research is focused on the development of long-acting, oral, dual and triple agonists, fixed-dose combinations, and small molecule drugs.Conclusion. GLP-1 receptor agonists are a class of effective and safe drugs for the treatment of diabetes and obesity, which is rapidly developing in the most advanced areas of pharmacy. A further development of this group and the solution of the identified problems will open up new opportunities for the treatment of diabetes and its complications.
- 9 January 2024
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 11 (4) , 347-380-380
Open AccessPhysiology and pharmacology of glucagon-like peptide-1 receptor
Modern approaches to the treatment of type 2 diabetes mellitus (T2DM) are aimed not only at glycemic control, but also at reducing cardiovascular risks. The increasing prevalence of the disease and the need for effective treatment options highlight the importance of glucagon-like peptide-1 (GLP-1) receptor agonists in the pharmacotherapy structure.The aim of the work was to review the literature regarding the physiology of GLP-1 and the therapeutic potential and development trends of its agonists.Materials and methods. The search for the review materials was carried out using the abstract databases of PubMed, Google Scholar and e-Library. The search was carried out for publications from 2000 to 2023, using the following keywords: “GLP-1”; “GLP-1R agonists”; “GIP”; “exenatide”; “liraglutide”; “dulaglutide”; “semaglutide”; “lixisenatide”; “albiglutide”; “taspoglutide” taking into account various spellings.Results. The interaction of almost all food components with enteroendocrine cells of the intestine leads to the secretion of incretins (primarily GLP-1) into the blood, triggering a complex of physiological reactions aimed primarily at the rapid utilization of incoming glucose (regulation of insulin and glucagon secretion), as well as the central regulation of dietary behavior (slowing gastric emptying and the formation of a feeling of satiety). A wide distribution of the GLP-1 receptor in various tissues and organs, its connection with intracellular signaling cascades aimed at launching energy-consuming remodeling (recovery) processes in endothelial cells, heart, neurons, beta cells, etc., is the basis for a wide range of pleiotropic effects of GLP-1 unrelated to its hypoglycemic effect. The discovery of synthetic GLP-1 receptor agonists with a long period of action has made it possible not only to therapeutically influence various parts of carbohydrate metabolism disorders, but also to increase the functional reserves of the target diabetes organs, reducing the risk of developing complications of the disease. Incretin-like drugs are well tolerated, with nausea being the most common side effect. The factors limiting a wider use of the drugs include their high cost and the preferred form of a subcutaneous solution. The current research is focused on the development of long-acting, oral, dual and triple agonists, fixed-dose combinations, and small molecule drugs.Conclusion. GLP-1 receptor agonists are a class of effective and safe drugs for the treatment of diabetes and obesity, which is rapidly developing in the most advanced areas of pharmacy. A further development of this group and the solution of the identified problems will open up new opportunities for the treatment of diabetes and its complications.
- Open Access
- 30 August 2023
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 69 (4) , 50-60
Characteristics of purchases of hypoglycemic agents in pharmacy retail sector in 2016–2020 years dynamics
BACKGROUND: Procurement of medicines reflects the demand and frequency of prescribing certain drugs, which makes it possible to assess the quality of medical care and compliance with standards. The Russian pharmaceutical market is dynamically developing and expanding, therefore, the commercial sector of drug circulation is a significant part of it and should be studied along with public procurement. Given the significant number of patients diagnosed with diabetes mellitus (DM) in our country, we considered it appropriate and interesting to analyze the structure and volume of turnover of antidiabetic drugs in the retail trade over five years.AIM: to assess the dynamics of the cost and sales volumes of hypoglycemic drugs in the commercial sector for 2019–2020 compared to 2016.MATERIALS AND METHODS: The analysis was made on the basis of the data of antidiabetic drugs purchases in Russian pharmacies in 2016 and 2019–2020, according to 95257 pharmacies data.RESULTS: In 2020, compared to 2016, we see a significant increase in the number of packages purchases (+14,952,897 rub.) and the purchases total amount (+9,377,975,722 rub.), in parallel with the increase in average price per box of the hypoglycemic drug +199, 57 rub. The average price for DPP4 decreased. The cost per pack of metformin remains one of the lowest, second only to glibenclamide and gliclazide. The most expensive drugs include GLP1 group representatives. Insulin purchases have halved, when budget for GLP1 have increased by 10 times, for SGLT2 by 9.5 times, and for DPP4 by 2.1 times. In 2020, metformin gliclazide, a combination of glibencladimide with metformin, glibenclamide and vildgaliptin remain leaders in the number of purchased packages. The purchase leaders in terms of budget share are: metformin, gliclazide, liraglutide, vildagliptin and dapagliflozinCONCLUSION: There are positive trends in the demand for more effective innovative hypoglycemic drugs, however, the affordability of drugs still dominates over the feasibility of their clinical use, and a high percentage of drug turnover in the commercial sector might indicates insufficient funding for drug provision for patients with diabetes mellitus.
- 30 August 2023
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 69 (4) , 50-60
Open AccessCharacteristics of purchases of hypoglycemic agents in pharmacy retail sector in 2016–2020 years dynamics
BACKGROUND: Procurement of medicines reflects the demand and frequency of prescribing certain drugs, which makes it possible to assess the quality of medical care and compliance with standards. The Russian pharmaceutical market is dynamically developing and expanding, therefore, the commercial sector of drug circulation is a significant part of it and should be studied along with public procurement. Given the significant number of patients diagnosed with diabetes mellitus (DM) in our country, we considered it appropriate and interesting to analyze the structure and volume of turnover of antidiabetic drugs in the retail trade over five years.AIM: to assess the dynamics of the cost and sales volumes of hypoglycemic drugs in the commercial sector for 2019–2020 compared to 2016.MATERIALS AND METHODS: The analysis was made on the basis of the data of antidiabetic drugs purchases in Russian pharmacies in 2016 and 2019–2020, according to 95257 pharmacies data.RESULTS: In 2020, compared to 2016, we see a significant increase in the number of packages purchases (+14,952,897 rub.) and the purchases total amount (+9,377,975,722 rub.), in parallel with the increase in average price per box of the hypoglycemic drug +199, 57 rub. The average price for DPP4 decreased. The cost per pack of metformin remains one of the lowest, second only to glibenclamide and gliclazide. The most expensive drugs include GLP1 group representatives. Insulin purchases have halved, when budget for GLP1 have increased by 10 times, for SGLT2 by 9.5 times, and for DPP4 by 2.1 times. In 2020, metformin gliclazide, a combination of glibencladimide with metformin, glibenclamide and vildgaliptin remain leaders in the number of purchased packages. The purchase leaders in terms of budget share are: metformin, gliclazide, liraglutide, vildagliptin and dapagliflozinCONCLUSION: There are positive trends in the demand for more effective innovative hypoglycemic drugs, however, the affordability of drugs still dominates over the feasibility of their clinical use, and a high percentage of drug turnover in the commercial sector might indicates insufficient funding for drug provision for patients with diabetes mellitus.